|[July 01, 2014]
BioRx Expands BioFeedback Program to Include Reports for Alpha-1 Antitrypsin Deficiency
CINCINNATI --(Business Wire)--
BioRx, a national specialty pharmacy provider, announced today that the
company has added alpha-1 antitrypsin deficiency (AATD) to its
BioFeedback health outcomes reporting program. With the addition of
AATD, BioRx now generates patient-specific outcome reports covering four
disease categories - AATD, hereditary angioedema, primary immune
deficiencies, and autoimmune neuropathies.
"Since the launch of our first BioFeedback program for neuropathies in
2013, we have developed a robust reporting system that can help measure
the health impact of some of the most costly specialty pharmaceutical
treatments out there," said Eric Hill, co-founder of BioRx. "That value,
in terms of health and cost, is of great interest to every stakeholder
in the pharmaceutical delivery chain - including patients, physicians,
payers and drug manufacturers."
AATD is an inherited condition that raises the risk of certain types of
lung disease, such as emphysema. (A small number of people may have
AAT-related liver or skin disease.) People with AAT deficiency do not
have enough of a protein called alpha-1 antitrypsin (AAT) in their
blood. Produced by the liver, AAT protein helps protect the lungs from
everyday irritants such as smoke, fumes, dust and pollen. Without the
protection of AAT, lungs can become damaged and suffer an accelerated
rate of decline.
Treatment for AAT deficiency may include some of the same products used
for a lung disease called chronic obstructive pulmonary disease (a.k.a.
COPD), including inhalers, supplemental oxygen or steroids. For
AAT-related lung disease, treatment may also consist of products known
as alpha-1 proteinase inhibitors (A1Pi). A1Pi products replace or
augment missing or deficient levels of circulating AAT protein in the
BioRx entered the AATD market in 2010 with a distribution agreement for
Aralast® NP and Glassia®, both A1Pi products from Baxter Healthcare. In
2012, BioRx was awarded distribution rights to another A1Pi product,
Zemaira®, from CSL Behring.
"With BioFeedback, our alpha-1 program will now be able to demonstrate
objective clinical measures of improvement or decline in a patient's
lung health," Hill said. "Moreover, we'll be able to see, visually, how
these changes might correspond with adherence to A1Pi treatment."
The BioFeedback reports for AATD will be sent each quarter to BioRx
physician referral sources. They will contain various measures of
AAT-related lung health and quality of life, including a patient's
forced expiratory volume in one second (FEV1), the most
commonly used measure of lung function over time. The reports will also
include important comparators of FEV1 to help physicians interpret their
patients' individual progress, including FEV1 vs. FEV6
and FEV1 vs. FEV1 predicted. This information is
charted along with individual patients' medication use, reported
respiratory infections, emergency room visits, hospital stays, missed
days of work or school, and a respiratory quality of life assessment.
Data is collected through a combination of home nursing visits and
routine, monthly telephone contact from BioRx consumer advocates.
In developing the BioFeedback program for AATD, BioRx consulted with
physicians and other thought leaders experienced in alpha-1 antitrypsin
deficiency. The company continues to develop and expand the uses of its
BioFeedback reporting platform. For more information or questions about
the program, call 866.44.BIORX (866.442.4679), email firstname.lastname@example.org,
or visit www.myalpha1solutions.com.
Based in Cincinnati, Ohio, BioRx is one of the nation's fastest growing
providers of specialty pharmaceuticals and infusion services, delivering
highly customized care for patients with certain rare and chronic
diseases. In addition to serving patients with alpha-1 antitrypsin
deficiency, BioRx offers pharmacy, nursing and education services to
patients with hemophilia, primary immune deficiencies, autoimmune
disorders, and hereditary angioedema. The company's clinical staff
reaches patients and physicians in all 50 states. To learn more about
BioRx and its products and services, visit www.biorx.com.
[ Back To Technology News's Homepage ]